CLS receives new order for the TRANBERG®-system from UTMB in the U.S.
Clinical Laserthermia Systems (CLS) (publ), has, through its subsidiary CLS Americas Inc., received an order for the TRANBERG®|Thermal Therapy System from the University of Texas Medical Branch (UTMB). CLS’ single use products are already in routine use at UTMB when it comes to treatment of early stage prostate cancer with MRI guided focal laser ablation (FLA) at UTMB. The TRANBERG-system will also be used in this FLA treatment procedure. The order value amounts to about 240 000 SEK.
- It is very gratifying that UTMB choses to purchase our system and continue to use our products. Dr. Eric Walser has so far treated about 20 patients, with early stage prostate cancer, using CLS’ accessories for MR-guided focal laser ablation and the products are performing very well, said Dan Mogren, CCO at CLS.
In October 2017 CLS entered into a supplier agreement with UTMB and with this UTMB placed a first order for CLS’ single use accessories for MRI guided laser ablation. Thereafter UTMB placed one additional order for single use products. These products have been used together with a laser system from another vendor, but UTMB has now decided to invest in CLS’ TRANBERG®|Thermal Therapy System.
CLS estimates the total addressable market (USA/EU/Japan) for focal laser ablation of benign prostatic hyperplasia (BPH) and malign localized prostate cancer to amount to about 500 000 treatments yearly.
More about University of Texas Medical Branch: www.utmb.edu
More about Dr. Eric Walser treatment with MRI guided laser ablation www.clinciallaser.com
This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version.
Lars-Erik Eriksson, CEO, Clinical Laserthermia Systems AB (publ)
Tel: +46 – (0)702 – 90 33 00 E-mail: email@example.com
Clinical Laserthermia Systems AB (publ), develops and sells the TRANBERG®|Thermal Therapy System and specially designed sterile disposable products for safe, gentle and effective treatment of cancerous tumors. The products are marketed for image-guided laser ablation and for treatment with immunostimulating interstitial laser thermotherapy, imILT®. The company, which is headquartered in Lund Sweden and have subsidiaries in Berlin, Germany and Boston, MA,USA, is listed Nasdaq First North under the ticker CLS B. Certified Adviser is Västra Hamnen Corporate Finance. Further information is available on the company’s website: www.clinicallaser.se